Time and geographical variations in utilization of endocrine therapy for breast cancer in Australia

Internal Medicine Journal

Volumn 41, Issue 2, 2011, Pages 162-166

  Vitry, A I ^a   Thai, L P ^a   Lu, C Y ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Aromatase inhibitors; Australia; Breast cancer; Drug use; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; TAMOXIFEN; TOREMIFENE;

ARTICLE; AUSTRALIA; BREAST CANCER; CANCER INCIDENCE; DRUG UTILIZATION; GEOGRAPHY; HORMONAL THERAPY; HUMAN; PRESCRIPTION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; AUSTRALIA; BREAST NEOPLASMS; FEMALE; HUMANS; TAMOXIFEN; TIME FACTORS;

EID: 79952021601     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2010.02304.x     Document Type: Article

References (19)

1. Australian Institute of Health and Welfare and National Breast and Ovarian Centre. Breast cancer in Australia: an overview, 2009. Cancer Series. Canberra: AIHW; 2009.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-717.
3. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
4. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J etal. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2009.
5. Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL etal. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008; 9: 23-8.
6. Coates A, Mouridsen H, Thurlimann B. Inappropriate ATAC on tamoxifen. Lancet Oncol 2008; 9: 315-16.
7. Drug Utilisation Sub-Committee PBAC. Australian statistics on medicines 2007. Canberra: Commonwealth of Australia; 2009.
8. Australian Bureau of Statistics. Australian Demographic Statistics. Canberra: Australian Bureau of Statistics; 2009.
9. Australian Institute of Health and Welfare and Australasian Association of Cancer. Cancer in Australia: an overview, 2008. Cancer Series 46. Canberra: AIHW; 2008.
10. Shen Y, Dong W, Feig BW, Ravdin P, Theriault RL, Giordano SH. Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004. Cancer 2009; 115: 2041-51.
11. Baum M, on behalf of the ATAC Trialists' Group. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in post-menopausal women. Breast Cancer Res Treat 2001; 69: 210.
12. Condon JR, Barnes T, Armstrong BK, Selva-Nayagam S, Elwood JM. Stage at diagnosis and cancer survival for Indigenous Australians in the Northern Territory. Med J Aust 2005; 182: 277-80.
13. Pharmaceutical Benefits Advisory Committee. Anastrozole, tablets, 1 mg, Arimidex®, July 2005. Public Summary Documents. Canberra: Australian government, Department of health and ageing; 2005.
14. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A. Quality of life of postmenopausal women in the ATAC ('Arimidex', tamoxifen, alone or in combination) trial after completion of 5years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 2006; 100: 273-84.
15. Fallowfield L. Quality of life issues in relation to the aromatase inhibitor. J Steroid Biochem Mol Biol 2007; 106: 168-72.
16. Seruga B, Tannock IF. Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol 2009; 27: 840-42.
17. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008; 26: 556-62.
18. Jackson TJ. Health technology assessment in Australia: challenges ahead. Med J Aust 2007; 187: 262-4.
19. Olver IN, Haines IE. What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century? Med J Aust 2009; 190: 74-7.